Phcog.Net logo
Submit

BROWSE ALL JOURNALS

    SEE ALL 6 JOURNALS
    Journal of Pharmacology and PharmacotherapeuticsNOW IN
    Article

    Efficacy and Safety of Oral Diclofenac Sustained release Versus Transdermal Diclofenac Patch in Chronic Musculoskeletal Pain: A Randomized, Open Label Trial

    Viraj Ashok Shinde1★, Mrunalini Kalikar2, Satyajeet Jagtap3, Ganesh N. Dakhale3, Mangesh Bankar3, Chaitali S. Bajait3, Vijay M. Motghare3, Ashlesha A. Pashilkar3, Latesh B. Raghute3, Ajita D. Khamkar3★ Corresponding author

    1. 1Department of Pharmacology, Government Medical College, Nagpur, Maharashtra, India.
    2. 2Department of Pharmacology, Andaman and Nicobar Islands Institute of Medical Sciences, Port Blair, Andaman and Nicobar, India.
    3. 3Department of Pharmaceutics, Dadasaheb Balpande College of Pharmacy, Nagpur, Maharashtra, India.

    CORRESPONDENCE

    Viraj Ashok Shinde

    Department of Pharmacology, Government Medical College, Nagpur, Maharashtra, India.

    shindevirajashok@gmail.com

    Received: 10-03-2017; Revised: 05-08-2017; Accepted: 11-12-2017.

    Volume 8, Issue 4 · pp. 166–171 · PUBLISHED 2017 · DOI: 10.4103/jpp.JPP_35_17

    View on J Pharmacol. Pharmacother. original site ↗

    ABSTRACT

    Introduction: To compare the efficacy, safety, and tolerability of transdermal patches of diclofenac sodium with oral diclofenac sustained release (SR) in patients of chronic musculoskeletal MSK pain conditions. Materials and Methods: The eligible patients were given either transdermal diclofenac patch or tablet diclofenac SR. Pain was assessed at 2 and 4 weeks using a visual analog scale. Adverse events were recorded. Patients with 18–65 years old of either gender with score of ≥4 on a 11‑item numeric rating scale‑numeric version of visual analog scale for pain with diagnosis of primary osteoarthritis (OA) of the knee or hand of at least 3 months duration, with independent radiological confirmation of OA or having pain associated with other MSK conditions such as soft‑tissue rheumatism, cervical and lumbar back pain, and fibromyalgia, of at least 3 months duration were included in this study. Results: Transdermal diclofenac diethylamine patch and tablet diclofenac sodium sustained release (SR) do not significantly differ in the reduction of numerical rating scores at the end of 4 weeks (P = 0.8393). Conclusion: Transdermal diclofenac was equi-efficacious as tablet diclofenac sodium SR in reducing pain due to chronic MSK pain conditions.

    KEYWORDS

    Open in new tab

    REFERENCES

    As published

    Showing references and in-text citations exactly as published.

      Cite this article

      SELECT FORMAT

      Shinde, V. A., Kalikar, M., Jagtap, S., Dakhale, G. N., Bankar, M., Bajait, C. S., Motghare, V. M., Pashilkar, A. A., Raghute, L. B., & Khamkar, A. D. (2017). Efficacy and Safety of Oral Diclofenac Sustained release Versus Transdermal Diclofenac Patch in Chronic Musculoskeletal Pain: A Randomized, Open Label Trial. Journal of Pharmacology and Pharmacotherapeutics, 8(4), 166–171. https://doi.org/10.4103/jpp.JPP_35_17